Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer
Science Advances · 2024-03-08 · 10 (10)
DOI: 10.1126/sciadv.adj6380 ↗At a glance
Journal article in Science Advances, published on 2024-03-08. Written by Shahad K Alsaiari and 17 co-authors. Institution: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Major MEDLINE topics: COVID-19, Zeolites. Cited 35 times so far (Crossref); 69 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS.
Abstract (original language)
Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework–8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
ORCID profiles: Shahad K Alsaiari, John L Daristotle, William Rothwell, Bujie Du, Linzixuan Zhang, Morteza Sarmadi, Lisa H Tostanoski, Nicole Hachmann, Dan H Barouch, Robert Langer, Ana Jaklenec
Funding
- NCI NIH HHS
Cite
APA
Alsaiari, S. K., Nadeef, S., Daristotle, J. L., Rothwell, W., Du, B., Garcia, J., Zhang, L., Sarmadi, M., Forster, T. A., Menon, N., Lin, S. Q., Tostanoski, L. H., Hachmann, N., Wang, E. Y., Ventura, J. D., Barouch, D. H., Langer, R., & Jaklenec, A. (2024). Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Science Advances, 10(10). https://doi.org/10.1126/sciadv.adj6380
Vancouver
Alsaiari SK, Nadeef S, Daristotle JL, Rothwell W, Du B, Garcia J, et al. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Science Advances. 2024;10(10). doi:10.1126/sciadv.adj6380
BibTeX
@article{Alsaiari2024,
author = {Alsaiari, Shahad K and Nadeef, Seba and Daristotle, John L and Rothwell, William and Du, Bujie and Garcia, Johnny and Zhang, Linzixuan and Sarmadi, Morteza and Forster, Timothy A and Menon, Nandita and Lin, Stacey Qiaohui and Tostanoski, Lisa H and Hachmann, Nicole and Wang, Erika Yan and Ventura, John D and Barouch, Dan H and Langer, Robert and Jaklenec, Ana},
title = {Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {10},
doi = {10.1126/sciadv.adj6380}
}
EUVIMED